BioCryst, NIH infectious news

BioCryst said NIH's National Institute of Allergy and Infectious Disease (NIAID) modified a 2013 contract to include an additional $2.4 million to develop the company's BCX4430 to treat hemorrhagic fever viruses. The additional funds will be used to conduct a dose-ranging efficacy study of an intramuscular formulation of BCX4430 and efficacy studies in non-human primates to assess effective dose ranges and schedules. The modification increases the value of the five-year contact to $24.4 million from $22 million if all options are exercised. ...